By Melissa Ritti ( August 21, 2024, 16:24 GMT | Insight) -- The University of Tokyo and Vedanta Biosciences say a series of patents relating to the promotion of T-cell growth are infringed by Seres Therapeutics and Nestlé Health Science’s microbiota “Vowst.” A three-day regimen treats recurrence of a potentially dangerous bacterial infection caused by antibiotic-induced microbiome disruption. Earlier this month, the defendants announced plans for a Nestlé affiliate to purchase Seres’ Vowst-related business for $155 million in cash.Just over one year after receiving approval from the US Food and Drug Administration, or FDA, for “Vowst,” Seres Therapeutics, Inc., Nestlé S.A., Société des Produits Nestlé S.A., Nestlé Health Science S.A., and Nestlé Health Science US Holdings, Inc. are facing allegations of patent infringement....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.